Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
600 participants
INTERVENTIONAL
2025-09-05
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The actual interventions to be evaluated have been co-designed with national stakeholders during an initial formative research stage.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination
NCT03576313
Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia
NCT02329301
Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria
NCT00425763
Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities
NCT04864444
Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania
NCT03640403
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A multi-centre, 2-arm, cluster-randomised trial evaluating two health system delivery strategies and a 3-arm nested individually randomised trial evaluating two new intervention strategies to enhance end-user adherence to post discharge malaria chemoprevention (PDMC) with dihydroartemisinin-piperaquine compared to the standard of care without adherence strategies.
Study sites: Health facilities with blood transfusion services in malaria-endemic areas in western Kenya.
Study Population:
Cluster inclusion criteria: health facilities with blood transfusion services offering in-patient care for children with severe anaemia and severe malaria. Exclusion criteria: primary health facilities without subservient lower-level health facilities.
Individual inclusion criteria: convalescent children aged \<10 years, weighing ≥5 kg admitted with severe anaemia (haemoglobin\<5g/dL) or severe malaria; clinically stable, able to take or switch to oral medication; post-transfusion Hb \>5g/dL. Exclusion criteria: blood loss due to trauma, malignancy, known bleeding disorders or sickle cell disease, known hypersensitivity to study drug, known heart conditions, non-resident in the study area, previous participation in the study, known need at enrolment for prohibited medication and scheduled surgery during the 4-month course of the study. HIV infection and cotrimoxazole prophylaxis are not exclusion criteria.
Study Interventions:
Cluster randomised trial: Hospitals will be randomised to one of two delivery platforms for PDMC (A or B). In delivery platform A, the initial course of PDMC will be delivered at discharge at the admitting facility. Subsequent courses will be dispensed during monthly visits to the health facility of their choice.In strategy B, all 3 courses will be dispensed at discharge.
Individually randomised trial: Three different adherence support strategies, including: SMS reminders to caregivers (arm a), Community Health Promoter (CHP) support through home visits (arm b), and a control arm comprising of no additional adherence support (arm c).
All participating children will receive standard in-hospital care for severe anaemia or severe malaria (blood transfusion, often combined parenteral artesunate, followed by a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication. Many children are likely to receive parenteral antibiotics as well as part of the standard of care.
Primary endpoints:
Cluster randomised trial: The proportion of eligible participants who were not prescribed the full 3 courses of PDMC.
Individually randomised trial: The proportion of children with incomplete adherence to the 9 doses of PDMC (three courses of 3-day treatments 3x3=9).
Secondary endpoints:
1. Clinical effectiveness (all-cause and malaria-specific sick-child clinic visits, all-cause and cause-specific readmissions and all-cause mortality by the end of week 14 after discharge.
2. Safety (incidence of serious adverse events).
3. Cost-effectiveness.
4. Acceptability and feasibility.
Follow-up procedures:
Children will be followed for 14 weeks (i.e., four weeks after the last PDMC course) through passive surveillance of clinic visits and hospitalisations. Each child will then be seen for an end-of-study visit towards the end of week 14. Children will also be visited at home for unannounced home visits one to three days from the last day of the last dose of each 3-day course of PDMC medication to assess adherence.
Sample size:
Cluster randomised trial: A sample size of 51 participants with complete follow-up recruited in 5 control and 5 intervention clusters (300 per arm) provides over 80% power to detect a risk difference of 20% from 35% in the control arm to 15% in the intervention clusters (RR=0.43), using a two-sided alpha of 0.05, and assuming an intra-cluster correlation coefficient (ICC) of 0.03,a coefficient of variation of 0.39 and a small-sample correction at the analysis stage, thus the t-distribution is assumed implying an adjustment in the degrees of freedom. Similarly, the same size would provide over 90% power to detect a risk difference of 23% from 35.0% to 12% (alpha = 0.05) (RR=0.34). To allow for a 15% loss to follow-up and enough power at the individual-level, we aim to recruit approximately 60 participants per cluster, or approximately 600 participants (300 per arm).
Individually randomised trial: A sample size of 147 participants in the control arm (c) and 147 in each of the two intervention arms (a and b), totalling 441 participants, would provide 90% power to detect a 50% reduction in the primary endpoint (proportion of children with incomplete adherence to the 9 doses of PDMC) from 36.8% in the control arm to 18.4% (RR=0.50) in any of the two intervention arms using a 1:1:1 allocation after accounting for the multiple comparisons (α = 0.025). A total of 519 participants (173 per arm) will be recruited to allow for a 15% loss to follow-up.
Data Analysis:
Risk ratios and corresponding 95% confidence intervals will be computed to compare treatment effects using multi-level mixed models accounting for clustering effects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Decentralized, monthly delivery of Post Discharge Malaria Chemoprevention (PDMC) drugs (Arm A)
Delivery of initial course of PDMC at discharge from the admitting facility. Referral to caregiver's peripheral facility of choice for delivery of subsequent monthly courses
SMS reminders; adherence support strategy a
Monthly SMS reminders sent to participants allocated to this adherence support intervention in both drug delivery arms (Centralized and decentralized arms)
Community Health Promoters (CHP) home visits; adherence support strategy b
Community Health Promoters' (CHPs) monthly reminder home visits conducted for participants allocated to this adherence support intervention in both drug delivery arms (Centralized and Decentralized arms)
No reminders; adherence support strategy c
No monthly reminders sent for participants allocated to this control adherence support intervention group in both drug delivery arms (Centralized and Decentralized arms)
Centralised delivery of Post Discharge Malaria Chemoprevention (PDMC) drugs at discharge (Arm B)
Delivery of all three courses of Post Discharge Malaria Chemoprevention (PDMC) drugs at discharge from the admitting facility.
SMS reminders; adherence support strategy a
Monthly SMS reminders sent to participants allocated to this adherence support intervention in both drug delivery arms (Centralized and decentralized arms)
Community Health Promoters (CHP) home visits; adherence support strategy b
Community Health Promoters' (CHPs) monthly reminder home visits conducted for participants allocated to this adherence support intervention in both drug delivery arms (Centralized and Decentralized arms)
No reminders; adherence support strategy c
No monthly reminders sent for participants allocated to this control adherence support intervention group in both drug delivery arms (Centralized and Decentralized arms)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SMS reminders; adherence support strategy a
Monthly SMS reminders sent to participants allocated to this adherence support intervention in both drug delivery arms (Centralized and decentralized arms)
Community Health Promoters (CHP) home visits; adherence support strategy b
Community Health Promoters' (CHPs) monthly reminder home visits conducted for participants allocated to this adherence support intervention in both drug delivery arms (Centralized and Decentralized arms)
No reminders; adherence support strategy c
No monthly reminders sent for participants allocated to this control adherence support intervention group in both drug delivery arms (Centralized and Decentralized arms)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Health facilities with blood transfusion services offering in-patient care for children with severe anaemia and severe malaria.
* \>=40 children per year admitted with severe anaemia or severe malaria
* Agreement to participate by facility management
* Located in areas with moderate to high malaria transmission
INDIVIDUAL PARTICIPANTS
* Aged \<10 years of both sexes
* Hospitalised with severe anaemia or severe malaria: Initially hospitalised with haemoglobin \<5.0 g/dl or PCV \<15%, or requirement for blood transfusion for other clinical reasons on or during admission to the hospital, or severe malaria, defined as a requirement for parenteral artesunate in the opinion of the treating clinician and/or the presence of microscopy or RDT confirmed Plasmodium infection
Exclusion Criteria
\- Health facilities without subservient lower-level health facilities
INDIVIDUAL PARTICIPANTS
* Recognised specific other causes of severe anaemia (i.e., trauma, haematological malignancy, known bleeding disorders, such as haemophilia)
* Sickle cell anaemia/sickle cell disease
* Body weight \<5 kg
9 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kenya Medical Research Institute
OTHER
Institut de Recherche Clinique du Benin (IRCB), Benin
UNKNOWN
Epicentre, Paris, France.
UNKNOWN
Institute of Research for Development, France
OTHER_GOV
Training Research Unit of Excellence, Blantyre, Malawi
UNKNOWN
Makerere University
OTHER
Centres for Disease Control and Prevention, Kenya.
OTHER
Liverpool School of Tropical Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Feiko ter Kuile, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
LSTM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kemri, Cghr
Kisumu, , Kenya
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.